Membrane fusion at the synapse: Janus faced synaptotagmin-1 helps to keep the fast paceOctober 30, 2008Imagine a bathtub with two soap bubbles colliding but never fusing. Then you add detergent, and the surface of the water goes flat as the walls of the bubbles collapse and merge. Dr. Christian Rosenmund, professor of neuroscience and molecular and human genetics at Baylor College of Medicine, and graduate student Mingshan Xue use that analogy to describe the action of synaptotagmin-1, which acts to catalyze the fusion of the membranes of tiny neurotransmitter-filled bubbles called vesicles with the wall membrane of a neuron. This action allows signals to flow between neurons. In a report in the current issue of Nature Structural and Molecular Biology, Rosenmund, Xue and colleagues from The University of Texas Southwestern Medical School at Dallas turn the notion of how synaptotagmin-1 accomplishes this task upside down, making an important step forward in understanding how synaptotagmin-1 accomplishes this task. In fact, said Xue, bringing the two membranes together involves both the top and bottom of a key domain of the protein. He demonstrated this in a series of elegant experiments that validated the importance of the bottom of the domain. "We are looking at the molecular mechanism of synaptic transmission or how neurons communicate in the brain," said Xue. Previously, experts had thought that only the top areas of the so-called C2B domain of synaptotagmin-1 were involved in facilitating fast neurotransmitter release. When the neuron is in a pre-synapse phase, it explodes in electrical activity that opens a channel allowing positively charged calcium ions to go to the balloon-shaped vesicles inside the presynapse to trigger the release of neurotransmitter. Transferring neurotransmitters from one neuron to another requires the fusion of the vesicle's membrane with its host plasma membrane. This allows the neurotransmitter to diffuse to the postsynaptic part of the synapse. Neurons send and receive information via two structures that make up the synapse. On the sending site, the electrical activity of the neuron needs to be rapidly converted into a chemical signal via release of a hormone or neurotransmitter. The trigger for this is the flux of calcium ions into the nerve terminal. The receiving neuron on the other site of the synapse detects the neurotransmitter via receptors and converts it again into electrical activity. It takes no more than 1/1,000th of a second for this to occur. Neuroscientists are not only fascinated by this astonishing speed, but they also recognize that disturbing the speed of synaptic transmission has deleterious consequences on brain function and can lead to various diseases of the nervous system including schizophrenia, depression, Parkinson's disease, epilepsy and Alzheimer's disease. Rosenmund and colleagues found that synaptotagmin-1 plays an important role in maintaining this speed. Bringing two fusing membranes close enough so that they fuse with each other is a crucial step in the process. The housekeeping machinery that accomplishes this in many biological processes is made up of the so-called SNARE proteins that form protein bundles across vesicle and plasma membranes, hurling the vesicle or balloon-like structure close to the membrane. While this process works very well, it is just too slow for synapses operating in a millisecond. "That's where synaptotagmin-1 and calcium come into the game," said Rosenmund. "Its C2B domain binds at the top site to calcium ions, allowing the subsequent attachment to of the two membranes." In their current work, Xue, Rosenmund and colleagues showed that the bottom of the C2B domain is also critical in bringing the membranes of the neuron together with the vesicle's membrane, allowing the release of neurotransmitter. "Nature invented SNARE first to help the process," said Xue. "But that did not take into account the high demand of the neurons. When the calcium comes, we need a fast neurotransmitter release. Nature then invented synaptotagmin-1 to respond to the calcium. It's a trigger. The molecule is turned on and interacts with both membranes." Baylor College of Medicine |
|||||||||||||||||||||
| Related Neurotransmitter Current Events and Neurotransmitter News Articles Researchers begin to decipher metabolism of sexual assault drug It's a naturally occurring brain chemical with an unwieldy name: 4-hydroxybutyrate (4-HB). Taken by mouth, it can be abused or used as a date-rape drug. New Down syndrome treatment suggested by Stanford/Packard study in mice At birth, children with Down syndrome aren't developmentally delayed. But as they age, these kids fall behind. Memory deficits inherent in Down syndrome hinder learning, making it hard for the brain to collect experiences needed for normal cognitive development. Cognitive dysfunction reversed in mouse model of Down syndrome A study by neuroscientist William C. Mobley, MD, PhD, chair of the Department of Neurosciences at the University of California, San Diego School of Medicine, and colleagues at Stanford University Medical School has demonstrated a possible new approach to slowing the inevitable progression of cognitive decline found in Down's syndrome. CSHL team solves structure of NMDA receptor unit that could be drug target for neurological diseases A team of scientists at Cold Spring Harbor Laboratory (CSHL) reports on Thursday their success in solving the molecular structure of a key portion of a cellular receptor implicated in Alzheimer's, Parkinson's, and other serious illnesses. Mood improves on low-fat, but not low-carb, diet plan After one year, a low-calorie, low-fat diet appears more beneficial to dieters' mood than a low-carbohydrate plan with the same number of calories. BUSM researchers show dieters can experience neurobiological similarities of drug addicts Researchers from Boston University School of Medicine (BUSM) have shown that intermittent access to foods rich in fat and sugar induces changes in the brain which are comparable to those observed in drug dependence. Scripps team shows diet switching can activate brain's stress system, lead to 'withdrawal' symptoms In research that sheds light on the perils of yo-yo dieting and repeated bouts of sugar-bingeing, researchers from The Scripps Research Institute have shown in animal models that cycling between periods of eating sweet and regular-tasting food can activate the brain's stress system and generate overeating, anxiety, and withdrawal-like symptoms. Widely used cholesterol-lowering drug may prevent progression Simvastatin, a commonly used, cholesterol-lowering drug, may prevent Parkinson's disease from progressing further. Neurological researchers at Rush University Medical Center conducted a study examining the use of the FDA-approved medication in mice with Parkinson's disease and found that the drug successfully reverses the biochemical, cellular and anatomical changes caused by the disease. Benefit of memantine in the treatment of Alzheimer's disease not proven There is no scientific proof that patients with moderate or severe Alzheimer's disease benefit from drugs containing the agent memantine. Changes in brain chemicals mark shifts in infant learning When do you first leave the nest? Early in development infants of many species experience important transitions-such as learning when to leave the protective presence of their mother to start exploring the wider world. More Neurotransmitter Current Events and Neurotransmitter News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||